Paper Licenses and Greenfield Dreams: NANO Nuclear's $13.5M Shortcut

BOISE, Idaho – October 01, 2026

The American nuclear renaissance is, at present, an architecture of paper. For all the legislative momentum and capital flowing into advanced reactors, the physical supply chains required to power them remain stubbornly theoretical. Today's announcement that Radnostix, Inc. is divesting its depleted uranium hexafluoride (DUF6) deconversion and fluorine extraction assets to NANO Nuclear Energy Inc. for $13.5 million is a perfect illustration of this modern industrial reality. It is a transaction that trades regulatory positioning for immediate liquidity, highlighting the structural bottlenecks of the U.S. nuclear fuel cycle and the unforgiving economics of greenfield infrastructure.

The deal, comprising $9.5 million in cash and $4.0 million in NANO common stock, transfers an unbuilt facility's intellectual property, engineering records, and—crucially—a U.S. Nuclear Regulatory Commission (NRC) 10 CFR Part 40 license. For NANO Nuclear, a company aggressively pursuing vertical integration to feed its future microreactors, the acquisition is a calculated shortcut through years of bureaucratic red tape. For Radnostix, it is a necessary shedding of heavy industrial ambitions to fund a high-stakes pivot toward the lucrative, fast-moving world of medical theranostics.

The Nuclear Fuel Scramble and Regulatory Shortcuts

To understand NANO Nuclear's motivation, one must look at the broader forces shaping the public square of energy policy. The Department of Energy is currently deploying billions through its HALEU Availability Program to establish a domestic supply of High-Assay Low-Enriched Uranium. Advanced microreactors, like NANO's proprietary ZEUS and ODIN designs, rely entirely on this specialized fuel. Yet, the domestic infrastructure to process, deconvert, and enrich this material is dangerously underdeveloped, leaving the U.S. reliant on foreign adversaries.

By acquiring Radnostix's NRC license (SUB-1011), NANO is not buying a functioning plant; it is buying a place at the front of the regulatory line. The NRC licensing process for nuclear material processing is a labyrinthine endeavor that can consume half a decade and tens of millions of dollars. As one energy sector analyst noted this morning, purchasing an existing, approved license—even for an unbuilt facility—shaves years off a company's development timeline.

NANO Nuclear has the balance sheet to make this bet. With approximately $577.9 million in working capital reported at the end of June 2026, the company is flush with cash from recent equity financings. However, it remains a pre-revenue development-stage entity. Securing the Lea County assets allows NANO to signal to the market—and to the Department of Energy—that it is actively assembling the physical footprint required to be a dominant player in the domestic fuel cycle.

A High-Stakes Pivot to Cancer Therapies

If NANO is buying time, Radnostix is buying survival and focus. Formerly known as International Isotopes Inc., the Idaho-based company rebranded late last year to reflect a strategic shift away from energy-sector isotopes and toward healthcare.

A forensic look at Radnostix's recent financials reveals exactly why this $9.5 million cash injection is a centering event. In its second-quarter 2026 filings, the company reported widening net losses exceeding $2.2 million for the year, compounded by voluntary product recalls and a temporary shutdown of its cobalt-60 hot cell operations. With just under $1.2 million in cash and equivalents on hand as of June 30, the burden of maintaining a dormant, capital-intensive nuclear fuel project in New Mexico was an unsustainable drag on its balance sheet.

"We have complete confidence in NANO to take these DUF6 deconversion and fluorine extraction assets across the finish line and fill a material need for the U.S. Nuclear Fuel Cycle industry," said Shahe Bagerdjian, Chief Executive Officer of Radnostix, in today's release. He added that the transaction provides "the best of both worlds," allowing the company to retain upside via NNE stock while fully focusing on radioisotope technologies in medical applications.

The radiopharmaceutical market, particularly theranostics—which combines diagnostic imaging with targeted internal radiation therapy—is experiencing explosive growth. Radnostix manufactures generic sodium iodide I-131 for thyroid cancer and supplies active pharmaceutical ingredients for third-party clients. Divesting the Lea County assets frees up capital to accelerate these high-margin R&D initiatives, particularly its recent partnerships to distribute radiopharmaceutical synthesis modules. It is a necessary retreat from the macro-infrastructure game to win in the micro-biological one.

Paper Assets Versus Greenfield Realities

Yet, any analysis of this transaction must critically examine the physical reality of the assets changing hands. The Lea County DUF6 facility has been a ghost project for over a decade. Originally envisioned during the early 2010s, construction was repeatedly delayed by the Fukushima disaster's chilling effect on the industry and plummeting natural gas prices.

This is not even the first time Radnostix has tried to offload the site. In late 2025, the company attempted to sell the plant and transfer the license to American Fuel Resources. That deal collapsed in March 2026 when the buyer failed to meet its payment deadlines. The legacy of this site is one of ambitious blueprints gathering dust.

NANO Nuclear is inheriting 640 acres of raw desert in Hobbs, New Mexico. Local economic development observers point out that while the county is highly supportive of nuclear projects—dubbing itself the "Energy Plex"—building a greenfield facility is fraught with localized friction. Notably, historical agreements regarding the site explicitly state that no water rights are to be transferred with the land. In the arid Southwest, establishing industrial-scale water access for a chemical processing plant is a formidable political and logistical hurdle.

Furthermore, NANO will not be the only entity vying for specialized labor and regulatory goodwill in the region. Eden Radioisotopes is currently advancing a proposed $1.4 billion medical-isotope facility in the same county. The competition for local resources, construction talent, and state-level environmental permitting will be fierce. Turning a paper license into poured concrete will test the operational capabilities of NANO's management team, who have yet to construct a commercial-scale facility of any kind.

The State, The Atom, and the Citizen

Ultimately, this transaction defines the current relationship between private enterprise and state-sponsored industrial policy. The federal government has recognized that the structural integrity of our energy grid requires a domestic nuclear fuel supply. By incentivizing the market, the state has created an environment where regulatory approvals themselves become highly liquid commodities.

The transfer of NRC license SUB-1011 remains subject to federal approval and a public comment period, a process that typically takes months. The 90 to 120-day closing window projected by the companies is optimistic but plausible, provided there are no significant interventions from environmental watchdogs or local stakeholders.

As we track the fraying and rebuilding of our modern infrastructure, the Radnostix-NANO deal serves as a bellwether. It demonstrates how capital flows to the path of least regulatory resistance. Radnostix has successfully monetized its regulatory foresight from a decade ago, securing the capital needed to fight cancer today. NANO Nuclear has purchased a crucial stepping stone in its quest to power the next generation of American industry. Whether that stepping stone ultimately leads to a functioning facility or remains a lucrative piece of paper in the New Mexico desert is a question only time, and immense amounts of capital, will answer.